12/06/2021
Nefrologie
Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147. doi: 10.1093/cid/ciab300.PMID: 33825869 Free PMC article. No abstract available.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
06/12/2023
Nefrologie
Dynamics of the Cellular and Humoral Immune Response After BNT162b2 Messenger Ribonucleic Acid Coronavirus Disease 2019 (COVID-19) Vaccination in COVID-19-Naive Nursing Home Residents.
J Infect Dis. 2021 Nov 22;224(10):1690-1693. doi: 10.1093/infdis/jiab458.PMID: 34514509dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2018
Neurologie
A new imaging technique to monitor disease activity in susac syndrome?
European Stroke Journal. 2018;3:3-204, p. 255dr. De Blauwe Sofiedr. Vanhooren Geertdr. De Vriese Andr. Lafaut Bartdr. Casselman Jan
06/05/2020
Nefrologie
IgG Antibody Response to SARS-Co-V-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis.
Am J Kidney Dis 2020dr. De Vriese Andr. Reynders Marijke
01/01/2022
Nefrologie
Epidemiology of native kidney disease in Flanders: results from the FCGG kidney biopsy registry.
Clin Kidney J 2022; 15: 1361-1372dr. De Vriese An
01/01/2021
Nefrologie
Covid-19 in dialysis: clinical impact, immune response, prevention and treatment.
Kidney Int 2022; 101:883-894dr. De Vriese An
06/12/2023
Laboratoriumgeneeskunde
“Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 vaccination in hemodialysis patients: a multicenter observational study”
J Am Soc Nephrol. 2021 Sep 29: ASN.2021070908. doi:10.1681/ASN.2021070908.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
06/12/2023
Laboratoriumgeneeskunde
“Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents”
J Infect Dis. 2021 Sep 13:jiab458.doi: 10.1093/infdis/jiab458. Online ahead of print.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
06/12/2023
Laboratoriumgeneeskunde
“Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in haemodialysis patients”
Clinical Kidney Journal. 2021 Aug 13;14(11):2446-2448. doi:10.1093/ckj/sfab147. eCollection 2021 Nov.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
04/07/2021
Laboratoriumgeneeskunde
“Humoral and cellular immunogenicity of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents”
Clin Infect Dis. 2021 Apr 7:ciab300. doi: 10.1093/cid/ciab300.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie
Noninvasive diagnosis of PLA2R-associated membranous nephropathy: a validation study.
Clin J Am Soc Nephrol 2021.dr. De Vriese An
01/01/2021
Nefrologie
Longevity and correlation with disease severity of the humoral and cellular response to SARS-CoV-2 infection in hemodialysis patients.
Clin Kidney J 2021; 14: 2446-2448.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie
Predictors and dynamics of the humoral and cellular immune response to SARS-CoV-2 mRNA vaccines in hemodialysis patients: a multicenter observational study.
J Am Soc Nephrol 2021.dr. Van Praet Jensdr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie
Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
J Infect Dis 2021.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie
Therapeutic trials in adult FSGS: lessons learned and the road forward.
Nat Rev Nephrol 2021; 17: 619-630.dr. De Vriese An
01/01/2021
Nefrologie
Humoral and cellular immunogenicity and safety of the BNT162b2 mRNA Covid-19 Vaccine in nursing home residents.
Clin Inf Dis 2021.dr. Van Praet Jensdr. Vandecasteele Stefaandr. De Vriese Andr. Reynders Marijke
01/01/2021
Nefrologie
Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial.
J Am Soc Nephrol 2021; 32: 1474-1483.dr. Van Der Meersch Hansdr. De Vriese An
01/01/2021
Nefrologie
A target antigen-based approach to the classification of membranous nephropathy.
Mayo Clin Proc 2021; 96: 577-591.dr. De Vriese An
01/01/2021
Nefrologie
Anticoagulation management in hemodialysis patients with atrial fibrillation: evidence and opinion.
Nephrol Dial Transplant 2021.dr. De Vriese An
01/01/2021
Nefrologie
Incidence, characteristics and outcome of Covid-19 in adult patients on kidney replacement therapy: a region-wide cohort study.
J Am Soc Nephrol 2021; 32: 385-396.dr. De Vriese An
01/01/2021
Nefrologie
PEXIVAS: The end of plasmapheresis for ANCA-associated vasculitis?
Clin J Am Soc Nephrol 2021; 16: 307-309.dr. De Vriese An
06/12/2023
Cardiologie
Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
Acta Cardiol. 2021 Sep 27:1-14. doi: 10.1080/00015385.2021.1976450.dr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. De Paepe Pascaledr. Delanote Joostdr. De Geeter Frankdr. De Vriese An Tavernier Renédr. Van Meirhaeghe Jandr. Lambert Greet
06/12/2023
Cardiologie
Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
Acta Cardiol. 2021 Sep 27:1-14.dr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. De Paepe Pascaledr. Delanote Joostdr. Debonnaire Philippedr. De Geeter Frankdr. De Vriese An Tavernier Renédr. Van Meirhaeghe Jan
06/12/2023
Cardiologie
Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications.
Acta Cardiol. 2021 Sep 27:1-14.dr. Willandt Barbaradr. Vantomme Nikolaasdr. Van Droogenbroeck Jandr. De Paepe Pascaledr. Delanote Joostdr. Debonnaire Philippedr. De Geeter Frankdr. De Vriese An Tavernier Renédr. Van Meirhaeghe Jan
01/01/2012
Neurologie
Reversion of cerebral artery stenoses due to tuberculomas with TNF-alpha antibodies.
Clin Neurol Neurosurg. 2012;114:1016-1018 (doi:10.1016/j.clineuro.2012.01.027)dr. Vandecasteele Stefaandr. Vanhooren Geertdr. De Vriese An
01/01/2021
Nefrologie
Incidence, characteristics and outcome of Covid-19 in adult patients on kidney replacement therapy: a region-wide cohort study.
J Am Soc Nephrol 2020dr. De Vriese An
01/01/2020
Nefrologie
Standardized Reporting of Monoclonal Immunoglobulin-Associated Renal Diseases: Recommendations from a Mayo Clinic/Renal Pathology Society Working Group.
Kidney Int 2020; 98: 310-313.dr. De Vriese An
06/12/2023
Nefrologie
In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?’
Am J Kidney Dis 2020.dr. De Vriese Andr. Reynders Marijke
06/12/2023
Laboratoriumgeneeskunde
“In Reply to ‘Is SARS-CoV-2 Serology Relevant for Hemodialysis Patients With COVID-19?”
Am J Kidney Dis. 2020 Jun 27:S0272-6386(20)30783-6. doi:10.1053/j.ajkd.2020.06.005dr. De Vriese Andr. Reynders Marijke
06/05/2020
Laboratoriumgeneeskunde
“IgG Antibody Response to SARS-CoV-2 Infection and Viral RNA Persistence in Patients on Maintenance Hemodialysis “.
American Journal of Kidney Diseases. 2020 Jun 5:S0272-6386(20)30733-2. doi: 10.1053/j.ajkd.2020.05.009.dr. De Vriese Andr. Reynders Marijke
11/08/2019
Radiologie en Medische Beeldvorming
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
J Am Soc Nephrol. 2019 Nov 8. pii: ASN.2019060579. doi: 10.1681/ASN.2019060579. [Epub ahead of print] PMID: 31704740 Select item 296314983.dr. Delanote Joostdr. De Vriese AnNefrologie
Other consequences from monoclonal immunoglobulins/fragments. Membranoproliferative glomerulonephritis and acquired Fanconi syndrome.
In: The Oxford Textbook of Clinical Nephrology.dr. De Vriese AnNefrologie
Membranoproliferative glomerulonephritis and cryoglobulinemic glomerulonephritis.
In: Comprehensive Clinical Nephrology, 6th Edition. Edited by John Feehally, Rick Johnson, Jürgen Floege, Marcello Tonelli.dr. De Vriese AnNefrologie
The approach to the patient with glomerular disease.
In: Scientific American Nephrology Dialysis and Transplantation.dr. De Vriese AnNefrologie
Membranous nephropathy.
In: National Kidney Foundation’s Primer on Kidney Diseases, 7th Edition. Edited by Scott Gilbert, Daniel Weiner, Andrew Bomback, Mark Perazella, Marcello Tonelli, pp. 188-197. ISBN: 978-0-323-47794-9dr. De Vriese AnNefrologie
Membranoproliferative glomerulonephritis.
In: Current Progress in Nephrology. Edited by Claudio Ponticelli and R Kasi Visweswaran, pp. 57-78. ISBN: 978-93-83989-19-5dr. De Vriese AnNefrologie
Glomerular diseases.
In: Cecil Essentials of Medicine. Edited by IJ Benjamin, pp 314-328. ISBN: 978-0-323-29617-5dr. De Vriese AnNefrologie
Indications to start kidney replacement therapy.
In: Management of acute kidney problems. Edited by A Jorres, C Ronco and Kellum, pp 471-479. ISBN: 978-3-540-69413-7dr. De Vriese An
01/01/2002
Nefrologie
Connexin-mimetic peptides: Influence on nitric oxide synthase- and cyclooxygenase-independent renal vasodilatation, basal renal blood flow and blood pressure in the rat.
In: EDHF 2002. Edited by PM VANHOUTTE, pp 78-86. ISBN 0-415-30853-4dr. De Vriese An
01/01/2000
Nefrologie
Folate restores the NO synthase- and cyclooxygenase-resistant renal vasodilator response to acetylcholine in diabetes.
In: EDHF 2000. Edited by PM VANHOUTTE, pp 360-369. ISBN 0-415-26904-0dr. De Vriese AnNefrologie
Factors influencing the progression of diabetic nephropathy.
In: Diabetic Nephropathy. Edited by J BONER, M COOPER, pp 75-96. ISBN 1-84184-076-9dr. De Vriese An
01/01/1999
Nefrologie
Acute renal failure in natural disasters.
In: Acute renal failure: a companion to Brenner & Rector’s the kidney. Edited by B MOLITORIS, W FINN, pp 236-245. ISBN 0-7216-9174-9dr. De Vriese An
01/01/1999
Nefrologie
Continuous renal replacement therapies in sepsis: do they matter?
In: Yearbook of Intensive Care and Emergency Medicine 1999, Edited by JL VINCENT, pp 611-620. ISSN 0942-5381.dr. De Vriese An
01/01/1992
Nefrologie
Influence of vasoactive intestinal polypeptide and NG-nitro-L-argininemethylester on cholinergic neurotransmission in the rat gastric fundus.
Eur J Pharmacol 1992; 221: 235-242.dr. De Vriese An
01/01/1995
Nefrologie
Carbamazepine hypersensitivity syndrome: report of 4 cases and review of the literature.
Medicine 1995; 74: 144-151dr. De Vriese An
01/01/1997
Nefrologie
Severe acute renal failure due to bromate intoxication: report of a case and discussion of management guidelines based on a review of the literature.
Nephrol Dial Transplant 1997; 12: 204-209.dr. De Vriese An
01/01/1998
Nefrologie
Rifampicin-associated acute renal failure: pathophysiologic, immunologic and clinical features.
Am J Kidney Dis 1998; 31: 108-115.dr. De Vriese An
01/01/1997
Nefrologie
Fundus fluorescein angiography in hypertensive renal failure.
Graefe Arch Clin Exp Ophtalmol 1997; 235: 749-754.dr. De Vriese An
01/01/1998
Nefrologie
Mild to moderate hyperhomocysteinaemia in cardiovascular disease.
Acta Cardiologica 1998; 53: 337-344.dr. De Vriese An
01/01/1999
Nefrologie
Cytokine removal during continuous hemofiltration in septic patients.
J Am Soc Nephrol 1999; 10: 846-853.dr. De Vriese An
01/01/1999
Nefrologie
Can inflammatory mediators be removed efficiently by continuous renal replacement techniques?
Intensive Care Med 1999; 25: 903-910.dr. De Vriese An
01/01/1999
Nefrologie
Evidence based therapy of acute renal failure.
Acta Clin Belg 1999; 54: 263-273.dr. De Vriese An
01/01/1999
Nefrologie
The role of selectins in glomerular leukocyte adhesion in rat anti-glomerular basement membrane glomerulonephritis.
J Am Soc Nephrol 1999; 10: 2510-2517.dr. De Vriese An
01/01/2000
Nefrologie
The role of dialyzer biocompatibility in acute renal failure.
Blood Purif 2000; 18: 1-12.dr. De Vriese An
01/01/2000
Nefrologie
Off-line analysis of red blood cell velocity in renal arterioles.
J Vasc Res 2000; 37: 26-31.dr. De Vriese An
01/01/2000
Nefrologie
Endothelial dysfunction in diabetes.
Br J Pharmacol 2000; 130: 963-974.dr. De Vriese An
01/01/2000
Nefrologie
The impaired renal vasodilator response attributed to endothelium-derived hyperpolarizing factor in streptozotocin-induced diabetic rats is restored by 5-methyltetrahydrofolate.
Diabetologia 2000; 43: 1116-1125.dr. De Vriese An
01/01/2001
Nefrologie
Intravital microscopy: an integrated evaluation of peritoneal function and structure.
Nephrol Dial Transplant 2001; 16: 657-660.dr. De Vriese An
01/01/2001
Nefrologie
Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes.
J Am Soc Nephrol 2001; 12: 993-1000.dr. De Vriese An
01/01/2001
Nefrologie
Evidence-based treatment of hypertension in diabetes type 2.
Acta Clin Belg 2001; 56: 96-102.dr. De Vriese An
01/01/2001
Nefrologie
Diabetes-induced renal microvascular dysfunction in the hydronephrotic kidney: role of nitric oxide.
Kidney Int 2001; 60: 202-210.dr. De Vriese An
01/01/2001
Nefrologie
Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane.
J Am Soc Nephrol 2001; 12: 1734-1741.dr. De Vriese An
01/01/2001
Nefrologie
Adsorption techniques and the use of sorbents.
Contrib Nephrol 2001; 133: 140-153.dr. De Vriese An
01/01/2001
Nefrologie
Neoangiogenesis in the peritoneal membrane: does it play a role in ultrafiltration failure ?
Nephrol Dial Transplant 2001; 16: 2143-2145.dr. De Vriese An
01/01/2001
Nefrologie
Glucotoxicity of the peritoneal membrane: the case for VEGF.
Nephrol Dial Transplant 2001; 16: 2299-2302dr. De Vriese An
01/01/2002
Nefrologie
Effects of connexin-mimetic peptides on nitric oxide synthase- and cyclooxygenase-independent renal vasodilatation, basal renal blood flow and blood pressure.
Kidney Int 2002; 61: 177-185.dr. De Vriese An
01/01/2002
Nefrologie
Hemodynamic effects of conventional and new peritoneal dialysis solutions on the microcirculation of the rat peritoneal membrane. Role of acidity, buffer choice, glucose concentration and glucose degradation products.
J Am Soc Nephrol 2002; 13: 480-489.dr. De Vriese An
01/01/2001
Nefrologie
Non anticoagulant effects of heparin: implications for animal models of peritoneal dialysis.
Perit Dial Int 2001; 21 (Suppl 3): S354-S356.dr. De Vriese An
01/01/2001
Nefrologie
What happens to the peritoneal membrane in long-term peritoneal dialysis ?
Perit Dial Int 2001; 21 (Suppl 3): S3-S12.dr. De Vriese An
01/01/2002
Nefrologie
Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?
Kidney Int 2002; 61: 1199-1209.dr. De Vriese An
01/01/2002
Nefrologie
Why are homocysteine levels elevated in renal failure? A metabolic approach.
J Lab Clin Med 2002; 139: 262-268.dr. De Vriese An
01/01/2002
Nefrologie
Experimental diabetes induces functional and structural changes in the peritoneum.
Kidney Int 2002; 62: 668-678.dr. De Vriese An
01/01/2002
Nefrologie
Compensatory glomerular hypertrophy following unilateral nephrectomy is strictly VEGF dependent.
Am J Physiol Endocrinol Metab 2002; 283: E362-366.dr. De Vriese An
01/01/2002
Nefrologie
Comparison of the radioiodinated serum albumin (RISA) dilution technique with direct volumetric measurements in animal models of peritoneal dialysis.
Perit Dial Int 2002; 22: 316-322.dr. De Vriese An
01/01/2002
Nefrologie
Amelioration of long-term renal changes in obese type 2 diabetic mice with a neutralizing vascular endothelial growth factor (VEGF)-antibody.
Diabetes 2002; 51: 3090-3094.dr. De Vriese An
01/01/2002
Nefrologie
Molecular imaging of early events in the development of the diabetic cardiomyopathy.
Amino Acids 2002; 23: 331-336.dr. De Vriese An
01/01/2002
Nefrologie
Interesting news in peritoneal dialysis.
Nephron 2002; 92: 763-771.dr. De Vriese An
01/01/2002
Nefrologie
The effects of heparin administration in an animal model of chronic dialysate exposure.
Perit Dial Int 2002; 22: 566-572.dr. De Vriese An
01/01/2002
Nefrologie
Increased leukocyte rolling in newly formed mesenteric vessels in the rat peritoneal membrane during peritoneal dialysis.
Perit Dial Int 2002; 22: 655-662.dr. De Vriese An
01/01/2003
Nefrologie
The statement that folate supraphysiological levels in uremic patients do not cause harm should not go unchallenged.
Kidney Int 2003; 63 :771-773.dr. De Vriese An
01/01/2003
Nefrologie
Recent concepts in the molecular biology of the peritoneal membrane – Implications for more biocompatible dialysis solutions.
Blood Purif 2003; 21: 14-23.dr. De Vriese An
01/01/2003
Nefrologie
Prevention and treatment of acute renal failure in sepsis.
J Am Soc Nephrol 2003; 14: 792-805dr. De Vriese An
01/01/2003
Nefrologie
Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis.
Am J Kidney Dis 2003; 41: 877-883.dr. De Vriese An
01/01/2003
Nefrologie
Effects of conventional and new peritoneal dialysis solutions on leukocyte recruitment in the microcirculation of the rat peritoneal membrane.
J Am Soc Nephrol 2003; 14: 1296-1306.dr. De Vriese An
01/01/2003
Nefrologie
Extensive acronecrosis as a manifestation of mixed cryoglobulinemia.
Acta Clin Belg 2003; 58: 58-61.dr. De Vriese An
01/01/2003
Nefrologie
Inhibition of AGE-RAGE interaction prevents hyperglycemia-induced fibrosis of the peritoneal membrane.
J Am Soc Nephrol 2003; 14: 2109-2118.dr. De Vriese An
01/01/2003
Nefrologie
The emerging role of VEGF in diabetic kidney disease.
Nephrol Dial Transplant 2003; 18: 1427-1430.dr. De Vriese An
01/01/2003
Nefrologie
Intravital videomicroscopy in peritoneal dialysis research.
Nefrologia 2003; 23 Suppl 3: 28-31.dr. De Vriese An
01/01/2003
Nefrologie
Antibiotic administration in an animal model of chronic dialysate exposure.
Perit Dial Int 2003; 23: 331-338.dr. De Vriese An
01/01/2003
Nefrologie
Creatine-supplementation decreases homocysteine in an animal model of uremia.
Kidney Int 2003; 64: 1331-1337.dr. De Vriese An
01/01/2003
Nefrologie
Effect of dialyzer membrane pore size on plasma homocysteine levels in hemodialysis patients.
Nephrol Dial Transplant 2003; 18: 2596-2600.dr. De Vriese An
01/01/2003
Nefrologie
Pharmacologic treatment of acute renal failure in sepsis.
Curr Opin Crit Care 2003; 9: 474-480.dr. De Vriese An
01/01/2003
Nefrologie
Prevention and nondialytic treatment of acute renal failure.
Curr Opin Crit Care 2003; 9: 481-490.dr. De Vriese An
01/01/2004
Nefrologie
Long-term renal changes in the Goto-Kakizaki rat, a model of lean type 2 diabetes.
Nephrol Dial Transplant 2004; 19: 1092-1097.dr. De Vriese An
01/01/2004
Nefrologie
Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study.
Eur J Gastroenterol Hepatol 2004; 16: 139-145.dr. De Vriese An
01/01/2004
Nefrologie
Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis: support for a risk in cirrhotic patients.
Liver Int 2004; 24: 63-68.dr. De Vriese An
01/01/2004
Nefrologie
Endothelium-derived hyperpolarizing factor – mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia.
Circulation 2004; 109: 2331-2336.dr. De Vriese An
01/01/2004
Nefrologie
The effects of peritoneal dialysate solutions on peritoneal host defense.
Perit Dial Int 2004; 24: 123-138.dr. De Vriese An
01/01/2004
Nefrologie
Prohepcidin accumulates in renal insufficiency.
Clin Chem Lab Med 2004; 42: 387-389.dr. De Vriese An
01/01/2004
Nefrologie
The role of vascular endothelial growth factor in renal pathophysiology.
Kidney Int 2004; 65: 2003-2017.dr. De Vriese An
01/01/2004
Nefrologie
Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane.
Kidney Int 2004; 66: 1257-1265.dr. De Vriese An
01/01/2005
Nefrologie
Analytical and biochemical aspects associated with supraphysiological creatine intake.
Clin Chim Acta 2005; 351: 217-219.dr. De Vriese An
01/01/2004
Nefrologie
Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients.
Kidney Int 2004; 66: 2422-2428.dr. De Vriese An
01/01/2004
Nefrologie
From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines.
Endocrine Rev 2004; 25: 971-1010.dr. De Vriese An
01/01/2005
Nefrologie
Cytochrome P450-2C11 mRNA is not expressed in endothelial cells dissected from rat renal arterioles.
Nephron Physiol 2005; 99: 43-49.dr. De Vriese An
01/01/2005
Nefrologie
Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
Horm Metab Res 2005; 37: 21-25.dr. De Vriese An
01/01/2004
Nefrologie
The role of hyperhomocysteinemia in relation to nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF)-mediated vasodilatation.
Cell Mol Biol 2004; 50: 911-916.dr. De Vriese An
01/01/2005
Nefrologie
The John F. Maher recipient lecture 2004: RAGE in the peritoneum.
Perit Dial Int 2005; 25: 8-11.dr. De Vriese An
01/01/2005
Nefrologie
Animal models in peritoneal dialysis research: a need for consensus.
Perit Dial Int 2005; 25: 16-24.dr. De Vriese An
01/01/2005
Nefrologie
Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered peritoneal dialysis solution in a rat model.
Kidney Int 2005; 76: 1559-1565.dr. De Vriese An
01/01/2005
Nefrologie
Immunopathological changes in a uraemic rat model for peritoneal dialysis.
Nephrol Dial Transplant 2005; 20: 1350-1361.dr. De Vriese An
01/01/2005
Nefrologie
Pathophysiological role of vascular endothelial growth factor in the remnant kidney.
Nephron Exp Nephrol 2005; 101: e9-15.dr. De Vriese An
01/01/2005
Nefrologie
Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane.
Nephron Exp Nephrol 2005; 101: e139-e145.dr. De Vriese An
01/01/2005
Nefrologie
Management of therapy-resistant systemic lupus erythematosus with rituximab: report of a case and review of the literature.
Acta Clin Belg 2005; 60: 102-105.dr. De Vriese An
01/01/2006
Nefrologie
A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat.
Nephrol Dial Transplant 2006; 21: 324-329.dr. De Vriese An
01/01/2005
Nefrologie
A case of secondary frosted branch angiitis in Behçet’s disease.
Bull Soc Belg Ophtalmol 2005; 298: 41-44.dr. De Vriese An
01/01/2006
Nefrologie
Activation of genes inducing cell-cycle arrest and of increased DNA repair in the hearts of rats with early streptozotocin-induced diabetes mellitus.
Med Sci Monit 2006; 12: BR68-74.dr. De Vriese An
01/01/2006
Nefrologie
Linezolid-induced inhibition of mitochondrial protein synthesis.
Clin Inf Dis 2006; 42: 1111-1117.dr. De Vriese An
01/01/2006
Nefrologie
What did we learn from animal models in peritoneal dialysis ?
Contrib Nephrol 2006; 150: 70-76.dr. De Vriese An
01/01/2006
Nefrologie
Effects of peritoneal dialysis on the vascular bed of the peritoneal membrane.
Contrib Nephrol 2006; 150: 84-89.dr. De Vriese An
01/01/2006
Nefrologie
RAGE-induced myofibroblast transdifferentiation of mesothelial cells contributes to peritoneal fibrosis in uremia.
Nephrol Dial Transplant 2006; 21: 2549-2555.dr. De Vriese An
01/01/2006
Nefrologie
Increased angiogenesis and permeability in the mesenteric microvasculature of rats with cirrhosis and portal hypertension: an in vivo study.
Liver Int 2006; 26: 889-898.dr. De Vriese An
01/01/2007
Nefrologie
Diet-induced hyperhomocysteinemia does not lead to large gene expression differences in rat aorta.
Atherosclerosis 2007; 193: 452-454.dr. De Vriese An
01/01/2006
Nefrologie
Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients.
Nephrol Dial Transplant 2006; 21: 3364-3367.dr. De Vriese An
01/01/2007
Nefrologie
Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer ?
Clin Sci 2007; 112: 281-289.dr. De Vriese An
01/01/2007
Nefrologie
Decreased leukocyte recruitment in the mesenteric microcirculation of rats with cirrhosis is partially restored by treatment with peginterferon: An in vivo study.
J Hepatol 2007; 46: 804-815.dr. De Vriese An
01/01/2007
Nefrologie
Prevention of contrast-induced nephropathy: a critical review.
Curr Opinion Nephrol Hypertens 2007; 16: 336-347.dr. De Vriese An
01/01/2007
Nefrologie
Renal side effects of anti-VEGF therapy in man: a new test system.
Nephrol Dial Transplant 2007, 22: 2778-80.dr. De Vriese An
01/01/2007
Nefrologie
Novel insights in the treatment of diabetic nephropathy.
Acta Clin Belg 2007; 62: 278-290.dr. De Vriese An
01/01/2008
Nefrologie
Guanidinocompounds after creatine supplementation in renal failure patients and their relation to inflammatory status.
Nephrol Dial Transplant 2008; 23: 1330-1335.dr. De Vriese An
01/01/2008
Nefrologie
Oral vitamin C administration increases lipid peroxidation in hemodialysis patients.
Nephron Clin Pract 2008; 108: c28-c34.dr. De Vriese An
01/01/2008
Nefrologie
Autologous transplantation of bone marrow mononuclear cells for limb ischemia in a Caucasian population with atherosclerosis obliterans.
J Intern Med 2008; 263: 395-403.dr. De Vriese An
01/01/2008
Nefrologie
Cellular therapy for critical limb ischemia. Author’s reply.
J Intern Med 2008; 264: 290.dr. De Vriese An
01/01/2009
Nefrologie
Comparison of the prognostic value of dipyridamole and dobutamine myocardial perfusion scintigraphy in end-stage renal disease.
Kidney Int 2009; 76: 428-436.dr. De Vriese An
01/01/2009
Nefrologie
Staphylococcus aureus infections in dialysis: what a nephrologist should know.
Clin J Am Soc Nephrol 2009; 4: 1388-1400.dr. De Vriese An
01/01/2010
Nefrologie
Diffuse alveolar bleeding caused by everolimus.
Chest 2010; 137: 456-459.dr. De Vriese An
01/01/2010
Nefrologie
Recent changes in vancomycin use in renal failure.
Kidney Int 2010; 77: 760-764.dr. De Vriese An
01/01/2011
Nefrologie
Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated -2a interferon.
Clin Nephrol 2011; 75 (Suppl 1): S1-S3.dr. De Vriese An
01/01/2011
Nefrologie
Vancomycin dosing in patients on intermittent hemodialysis.
Semin Dial 2011; 24: 50-55.dr. De Vriese An
01/01/2011
Nefrologie
Fluctuations of haemoglobinaemia in chronic hemodialysis patients.
Acta Clin Belg 2011; 66: 123-128.dr. De Vriese An
01/01/2011
Nefrologie
Implementation of a dose calculator for vancomycin to achieve target through levels of 15-20 mg:ml in persons undergoing hemodialysis.
Clin Inf Dis 2011; 53: 124-129.dr. De Vriese An
01/01/2012
Nefrologie
Should we screen for coronary artery disease in asymptomatic chronic hemodialysis patients ?
Kidney Int 2012; 81: 143-151.dr. De Vriese An
01/01/2012
Nefrologie
Reversion of cerebral artery stenoses due to tuberculomas with TNF-alpha antibodies.
Clin Neurol Neurosurg 2012; 114: 1016-8.dr. De Vriese An
01/01/2013
Nefrologie
The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties.
J Antimicrob Chemother 2013; 68: 743-8.dr. De Vriese An
01/01/2013
Nefrologie
Global protein and histone arginine methylation are affected in a tissue-specific manner in a rat model of diet-induced hyperhomocysteinemia.
Biochim Biophys Acta 2013; 1832: 1708-14.dr. De Vriese An
01/01/2013
Nefrologie
Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall.
J Am Soc Nephrol 2013; 24: 1981-94.dr. De Vriese An
01/01/2014
Nefrologie
Vitamin K2 Supplementation in Hemodialysis Patients: a Randomized Dosefinding Study.
Nephrol Dial Transplant 2014; 29: 1385-90.dr. De Vriese An
01/01/2013
Nefrologie
Cystatin C versus creatinine for kidney function-based risk.
N Engl J Med 2013; 369: 2458-9.dr. De Vriese An
01/01/2014
Nefrologie
Vancomycin: the tale of the vanquisher and the Pyrrhic victory.
Perit Dial Int 2014; 34: 154-61.dr. De Vriese An
01/01/2015
Nefrologie
Hemodialysis catheter design and catheter performance: a randomized controlled trial.
Am J Kidney Dis 2014; 64: 902-8. Erratum in Am J Kidney Dis 2015; 65: 810.dr. De Vriese An
01/01/2014
Nefrologie
A bone scan, no mistake!
J Clin Endocrinol Metab 2014; 99: 4447-8.dr. De Vriese An
01/01/2015
Nefrologie
Dose finding of rivaroxaban in hemodialysis patients.
Am J Kidney Dis 2015; 66: 91-8.dr. De Vriese An
01/01/2015
Nefrologie
High homocysteine induces betaine depletion.
Biosci Rep 2015; 35: pii:e00222.dr. De Vriese An
01/01/2015
Nefrologie
C4d as a diagnostic tool in the diagnosis of proliferative glomerulonephritis.
J Am Soc Nephrol 2015;26:2852-2859.dr. De Vriese An
01/01/2015
Nefrologie
Biomarkers in glomerular diseases: putting the cart before the wheel?
Nephrol Dial Transplant 2015; 30: 885-890.dr. De Vriese An
01/01/2015
Nefrologie
Opponent’s comments.
Nephrol Dial Transplant 2015; 30: 898-899.dr. De Vriese An
01/01/2015
Nefrologie
In reply to “Hemodialysis catheters: which design is more cost-effective? And “Use of an uncensored primary outcome in a catheter design trial”.
Am J Kidney Dis 2015; 66: 171.dr. De Vriese An
01/01/2015
Nefrologie
Glomerular disease caused by dysregulation of the complement alternative pathway: an etiologic approach.
J Am Soc Nephrol 2015; 26: 2917-2929.dr. De Vriese An
01/01/2016
Nefrologie
C3 glomerulonephritis and autoimmune disease: more than a fortuitous association?
J Nephrol 2016; 29: 203-9.dr. De Vriese An
01/01/2016
Nefrologie
Mayo Clinic/ Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of Glomerulonephritis.
J Am Soc Nephrol 2016; 27: 1278-87.dr. De Vriese An
01/01/2016
Nefrologie
Diagnosis of complement alternative pathway disorders.
Kidney Int 2016; 89: 278-288.dr. De Vriese An
01/01/2016
Nefrologie
The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials.
Clin Kidney J 2016; 9: 273-279.dr. De Vriese An
01/01/2016
Nefrologie
The atrial fibrillation conundrum in dialysis patients.
Am Heart J 2016; 174: 111-119.dr. De Vriese An
01/01/2016
Nefrologie
Temporal IgG subtype changes in recurrent idiopathic membranous nephropathy.
Am J Transplant 2016; 16: 2964-72.dr. De Vriese An
01/01/2023
Nefrologie
A proposal for a serology-driven approach to membranous nephropathy.
J Am Soc Nephrol 2017;28:421-430.dr. De Vriese An
01/01/2016
Nefrologie
Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a meta-analysis.
Am Heart J 2016; 184: 37-46.dr. De Vriese An
01/01/2017
Nefrologie
Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference.
Kidney Int 2017;91:539-551.dr. De Vriese An
01/01/2017
Nefrologie
Fibromuscular dysplasia: results of a multicenter study in Flanders.
Vasa 2017;46:211-218.dr. De Vriese An
01/01/2017
Nefrologie
Proposal for Standardized Grading of Chronic Changes in Native Kidney Biopsy Specimens.
Kidney Int 2017;91:787-789.dr. De Vriese An
01/01/2017
Nefrologie
Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: Results of a proteomic analysis.
Nephrol Dial Transplant 2017;32(suppl_1):i139-i145.dr. De Vriese An
01/01/2017
Nefrologie
What are we missing in the clinical trials of focal segmental glomerulosclerosis?
Nephrol Dial Transplant 2017;32(suppl_1):i14-i21.dr. De Vriese An
01/01/2017
Nefrologie
Should statins be banned from dialysis?
J Am Soc Nephrol 2017;28:1675-1676.dr. De Vriese An
01/01/2017
Nefrologie
Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings.
Clin Nephrol 2017;88:277-283.dr. De Vriese An
01/01/2017
Nefrologie
Interstitial immunostaining and renal outcomes in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
Am J Nephrol 2017;46:231-238.dr. De Vriese An
01/01/2017
Nefrologie
The incidence of primary versus secondary focal and segmental glomerulosclerosis: a clinicopathological study.
Mayo Clin Proc 2017;92:1772-1781.dr. De Vriese An
01/01/2018
Nefrologie
Differentiating primary, genetic and secondary FSGS in adults: a clinicopathologic approach.
J Am Soc Nephrol 2018; 29: 759-774.dr. De Vriese An
01/01/2018
Nefrologie
Measurement of pulse wave velocity, augmentation index and central pulse pressure in atrial fibrillation: a proof of concept study.
J Am Soc Hypertens 2018; 12: 627-632.dr. De Vriese An
01/01/2018
Nefrologie
C3 glomerulopathy: Ten years’ experience at the Mayo Clinic.
Mayo Clin Proc 2018; 93: 991-1008.dr. De Vriese An
01/01/2019
Nefrologie
Non-invasive diagnosis of primary membranous nephropathy using Phospholipase A2 receptor antibodies.
Kidney Int 2019dr. De Vriese An
01/01/2020
Nefrologie
Evaluation of vitamin K status and rationale for vitamin K supplementation in dialysis patients.
Nephrol Dial Transplant 2019.dr. De Vriese AnNefrologie
Primary vs Secondary Membranous Nephropathy: does it make sense?
Mayo Consensus Meeting on Membranous Nephropathy, Rochester (on-line)2022-10-29dr. De Vriese AnNefrologie
Device Puncturability.
aXess Pivotal Investigator Meeting Barcelona2022-10-22dr. De Vriese AnNefrologie
Infectious complications in hemodialysis and peritoneal dialysis.
Nephro Update Europe Amsterdam2022-09-09dr. De Vriese AnNefrologie
Oral anticoagulation in dialysis.
IVth South-American Conference on Dialysis and Transplantation, Quito2022-06-23dr. De Vriese AnNefrologie
Oral anticoagulation in CKD: practical questions and pragmatic answers.
Brugge2022-03-18dr. De Vriese AnNefrologie
Anticoagulation & Atrial fibrillation in CKD.
https://www.youtube.com/watch?v=vlzFdCilljY2022-03-11dr. De Vriese AnNefrologie
Voor- en nadelen van coumarines vs DOAC.
31e Digitale workshop Nierziekten Papendal (on-line)2020-12-09dr. De Vriese AnNefrologie
“Infectious complications in hemodialysis and peritoneal dialysis”
Vienna2021-09-11dr. De Vriese AnNefrologie
“Novel insights in the diagnosis of membranous nephropathy”
Parijs (online)2021-04-27dr. De Vriese AnNefrologie
“Attenuation of vascular calcification in hemodialysis patients with vitamin K: feasible goal or beautiful fantasy?”
Aachen2020-11-12dr. De Vriese AnNefrologie
“Infectious complications in hemodialysis and peritoneal dialysis”
Europe, Den Hague2020-09-19dr. De Vriese AnNefrologie
“Infectieziekten in hemodialyse en peritoneale dialyse” en “Anticoagulatie strategieën bij dialyse”
Vaals, Nederlanddr. De Vriese AnNefrologie
”Limitations of the long-term use of peritoneal dialysis” and ”The prognosis of acute renal failure”.
Iasi (Roemenië)dr. De Vriese AnNefrologie
“Influence of an anti-CD11b antibody in glomerular hemodynamics and leukocyte adhesion in rat glomerulonephritis”.
Riminidr. De Vriese AnNefrologie
“Influence of cytokine removal with continuous venovenous hemofiltration (CVVH) on systemic hemodynamics in sepsis”.
Riminidr. De Vriese AnNefrologie
“Cytokine removal with continuous venovenous hemofiltration (CVVH) in sepsis: relative importance of adsorption and convective elimination”.
Riminidr. De Vriese AnNefrologie
“The hydronephrotic rat kidney as a model to study the renal microvascular changes in diabetes”.
Tübingendr. De Vriese AnNefrologie
“Impaired endothelium derived hyperpolarizing factor – mediated renal vasodilatory response in diabetes”.
63ste Wetenschappelijke Vergadering van de Nederlandse Vereniging voor Nefrologie, Arnhemdr. De Vriese AnNefrologie
“Antibodies against vascular endothelial growth factor decrease hyperfiltration and albuminuria in experimental diabetes”
the XXXVI Congress of the European Renal Association, Madriddr. De Vriese AnNefrologie
”Endothelial dysfunction in diabetes: a role for folate?”,
Homocysteine Working Group, Nijmegendr. De Vriese AnNefrologie
“Impaired endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatory response in diabetes: restoration with folate”
the 32nd Annual Meeting of the American Society of Nephrology, Miamidr. De Vriese AnNefrologie
“The diabetic rat model to study high glucose-induced peritoneal membrane changes using the videomicroscope system”
PD solutions for the 21st century: experimental and clinical models for evaluation of new PD solutions, Brusselsdr. De Vriese AnNefrologie
”Diabetes as a model to study the effects of high dialysate glucose levels on peritoneal structure and function”
4th European Peritoneal Dialysis Meeting, 3rd International Meeting on Aminal Models in Peritoneal Dialysis, Madriddr. De Vriese AnNefrologie
“Hyperpermeability of the peritoneal membrane in diabetes: role of VEGF”
4th European Peritoneal Dialysis Meeting, Madriddr. De Vriese AnNefrologie
”Role of vascular endothelial growth factor in diabetes”
Symposium Renal Microcirculation, Heidelbergdr. De Vriese AnNefrologie
“Endothelial dysfunction in the diabetic renal microcirculation: restoration with folate”
XXXVII Congress of the European Renal Association, First combined congres with European Kidney Research Association, Nicedr. De Vriese AnNefrologie
“Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes”
Wetenschappelijke Vergadering van de Nederlandse Vereniging voor Nefrologie, Nijmegendr. De Vriese AnNefrologie
“Biocompatibility Issues in Peritoneal Dialysis”
5th Course of the Dialysis Academy, Gentdr. De Vriese AnNefrologie
“How do peritoneal dialysis fluids influence peritoneal vascular reactivity and neoangiogenesis ?”
IX Congress of the International Society for Peritoneal Dialysis, Montréaldr. De Vriese AnNefrologie
“The effects of heparin administration in an animal model of chronic dialysate exposure”
IX Congress of the International Society for Peritoneal Dialysis, 4th International Meeting on Aminal Models in Peritoneal Dialysis, Montréaldr. De Vriese AnNefrologie
“Effects of connexin-mimetic peptides on endothelium-derived hyperpolarizing factor (EDHF) – mediated renal vasodilatation, basal renal blood flow and blood pressure”.
XXXVIII Congress of the European Renal Association, Wenendr. De Vriese AnNefrologie
“Role of glucose degradation products in PD”
7th Course of the Dialysis Academy, Gentdr. De Vriese AnNefrologie
“Intravital microscopy to evaluate functional properties of standard and pH neutral dialysis solutions”
Fifth European Peritoneal Dialysis Conference, Brusseldr. De Vriese AnNefrologie
“Mechanisms of glucose toxicity to the peritoneal membrane”
35th Annual Meeting of the American Society of Nephrology, Philadelphiadr. De Vriese AnNefrologie
“Neoangiogenesis in the peritoneal membrane”
World Congress of Nephrology, Berlindr. De Vriese AnNefrologie
“The effect of diabetes on the peritoneal membrane: experimental results and clinical correlations”
36th Annual Meeting of the American Society of Nephrology, San Diegodr. De Vriese AnNefrologie
“RAGE in the peritoneum”
First Joint Meeting of the International Society of Peritoneal Dialysis and the European Peritoneal Dialysis Meeting, Amsterdamdr. De Vriese AnNefrologie
“On VEGF – the most important growth factor in PD membrane alterations”,
First Joint Meeting of the International Society of Peritoneal Dialysis and the European Peritoneal Dialysis Meeting, Amsterdamdr. De Vriese AnNefrologie
“Controlling angiogenesis”
7th European Peritoneal Dialysis Meeting, Praagdr. De Vriese AnNefrologie
“Difficulties in setting up an animal model of peritonitis”,
ANIMOD Meeting, 7th European Peritoneal Dialysis Meeting, Praagdr. De Vriese AnNefrologie
“Peritoneal and extraperitoneal effects of GDPs and AGEs”
The 11th Congress of the International Society of Peritoneal Dialysis, Hong-Kongdr. De Vriese AnNefrologie
“Diagnosis and treatment of CAD in ESRD: Can we do better?”
9th European Peritoneal Dialysis Meeting, Strassbourgdr. De Vriese AnNefrologie
“New insights in pharmacokinetics and pharmacodynamics of antibiotics: implications for the treatment of peritonitis “
49th ERA-EDTA Congress, Parijsdr. De Vriese AnNefrologie
“Hemodialysis, do we need individualized treatment prescriptions ?”
2nd International Renal Meeting in Sardinia, Cagliaridr. De Vriese AnNefrologie
“Vitamin K antagonists in dialysis: navigating between Scylla and Charybdis”
First International Renal Conference, Bruggedr. De Vriese AnNefrologie
“The evidence for intensive dialysis: frequent and prolonged dialysis, hemodiafiltration”, “Vitamin K and vascular calcifications”, and “Hemodialysis catheters: does design matter ?”
Simposio Fronteras 2014, Santiago de Chilidr. De Vriese AnNefrologie
“Old and new antibiotics in dialysis”
3rd International Renal Meeting in Sardinia, Cagliaridr. De Vriese AnNefrologie
“Oral anticoagulation in dialysis patients: challenges and opportunities”
Cardiology Divisional Grand Rounds, Mazankowski Alberta Heart Institute, Edmontondr. De Vriese AnNefrologie
“Oral anticoagulation in dialysis patients”, and “The use of vancomycin in CKD, hemodialysis and peritoneal dialysis”
Srinagardr. De Vriese AnNefrologie
“Oral anticoagulation in hemodialysis: new insights”
First Mayo Clinic Nephrology Meeting in Argentina, Buenos Airesdr. De Vriese AnNefrologie
“Should we use vitamin K antagonists in hemodialysis patients?”,
Trondheim Renal Research Group/Norwegian Society of Nephrology, Tröndheimdr. De Vriese AnNefrologie
“Oral anticoagulation in dialysis: alternatives to warfarin.”
Congres of the Iranian Society of Nephrology, Shirazdr. De Vriese AnNefrologie
“Oral anticoagulation in hemodialysis patients: challenges and opportunities”
34th Biennal Congres of the Nordic Society of Nephrology, Malmödr. De Vriese AnNefrologie
“Infectious complications of peritoneal dialysis”
Second International Renal Conference, Bruggedr. De Vriese AnNefrologie
“Serology-based approach to membranous nephropathy”
Third International Conference on Membranous Nephropathy, Bergamodr. De Vriese AnNefrologie